Ventyx Biosciences Inc. (VTYX)
NASDAQ: VTYX
· Real-Time Price · USD
2.46
0.06 (2.50%)
At close: Jun 26, 2025, 1:52 PM
2.50% (1D)
| Bid | 2.45 |
| Market Cap | 174.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -123.99M |
| EPS (ttm) | -1.74 |
| PE Ratio (ttm) | -1.41 |
| Forward PE | -1.28 |
| Analyst | Buy |
| Ask | 2.46 |
| Volume | 773,298 |
| Avg. Volume (20D) | 1,653,359.1 |
| Open | 2.42 |
| Previous Close | 2.40 |
| Day's Range | 2.38 - 2.50 |
| 52-Week Range | 0.78 - 3.39 |
| Beta | 0.85 |
About VTYX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VTYX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VTYX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts9 months ago
+6.96%
Ventyx Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
11 months ago
-22.71%
Ventyx Biosciences shares are trading lower after the company announced its Phase 2 trial of VTX958 for Crohn's disease did not meet its primary endpoint.
